Todd C. Johnson

Aspen Marketing Group Ltd. provides marketing and media services. It serves mobile telecommunications, foodservice, media storage, on trade and off trade, home improvement, and leisure markets. The company was founded on October 12, 2004 and is headquartered in Woking, the United Kingdom.

Reach Contact Ltd. operates as an outsources international contract sales organization. It offers tactical services, mystery shopping, merchandising, category management, airport services, store experts, field marketing, analytics, retail promotions, call center support, retail execution, and telemarketing. The company was founded on September 15, 1975 and is headquartered in Woking, the United Kingdom.

Reach Holdings Ltd. is a British company that focuses on sales execution and retail technology. The company is based in Woking, UK. and has subsidiaries in United Kingdom. The company was founded in 1975. The CEO is Mark Paul Smith. Reach Holdings was acquired by Acosta, Inc. on February 03, 2017.

Part of Acosta, Inc., Acosta RH Ltd. is a holding British company that provides software sales and marketing services through its subsidiaries. The company is based in Woking, UK and was founded in 2017.

Part of Reach Holdings Ltd., ShopSmart Agency Ltd. is a field marketing agency based in Crawley, UK. The British company combines people, data-led insight, and operational excellence to achieve success for brands. The company's hands-on approach means clients see them as an extension of their team with a shared ambition to succeed. The company provides support to both the client and the field team, ensuring that their team is doing as much as they can. The company has designed and implemented an effective field sales service, with results that achieve success across all areas.

Part of Reach Holdings Ltd., Disrupt Ltd. is a British company that conducts a clinical study called the phase 3 disrupt study of exebacase. The company is based in Woking, UK and was founded in 2008. The study aims to evaluate the efficacy and safety of exebacase in approximately 350 patients with complicated staph aureus bacteremia, including right-sided endocarditis. The primary efficacy endpoint of the study is clinical response at day 14 in patients with MRSA bacteremia, including right-sided endocarditis. Secondary endpoints include clinical response at day 14 in all staph aureus patients (MRSA and methicillin-sensitive staph aureus (MSSA)), 30-day all-cause mortality in MRSA patients, and clinical response at later timepoints.